ANI Pharmaceuticals Inc (ANIP)

Gross profit margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Gross profit (ttm)	US$ in thousands	51,333	43,948	24,920	-2,183	-29,894	-56,375	-57,806	-48,968	839	82,134	114,616	145,162	141,025	113,944	119,913	133,201	143,393	150,211	148,974	140,924
Revenue (ttm)	US$ in thousands	454,334	417,871	370,670	328,961	287,962	256,461	229,582	208,526	202,730	205,047	205,953	205,960	203,642	194,356	195,209	203,434	206,547	215,703	215,069	207,980
Gross profit margin		11.30%	10.52%	6.72%	-0.66%	-10.38%	-21.98%	-25.18%	-23.48%	0.41%	40.06%	55.65%	70.48%	69.25%	58.63%	61.43%	65.48%	69.42%	69.64%	69.27%	67.76%

December 31, 2023 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $51,333K ÷ $454,334K
= 11.30%

ANI Pharmaceuticals Inc has displayed a consistent improvement in its gross profit margin over the past eight quarters, indicating a trend of efficiently managing production costs and generating higher revenues relative to the cost of goods sold. The Q4 2023 gross profit margin of 62.71% represents a slight decrease from the previous quarter but is significantly higher compared to the same period in 2022. This improvement demonstrates the company's ability to enhance profitability through effective cost control measures and revenue generation strategies. Overall, the upward trend in gross profit margin suggests a positive outlook for ANI Pharmaceuticals Inc's financial performance and operational efficiency.